

SUPPLEMENTARY MATERIALS

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis

Running Title: Rapid Itch Improvement and Skin Clearance with Upadacitinib vs Placebo and vs Dupilumab in AD

Eric L. Simpson¹ • Jonathan I. Silverberg² • Vimal H. Prajapati³⁻⁷ • Kilian Eyerich⁸ • Norito Katoh⁹ • Mark Boguniewicz^{10,11} • Emma Guttman-Yassky¹² • E. James Song¹³ • Wan-Ju Lee¹⁴ • Henrique D. Teixeira¹⁴ • Tianshuang Wu¹⁴ • Cristina Sancho Sanchez¹⁴ • Namita Vigna¹⁴ • Brian M. Calimlim¹⁴ • Marjolein de Bruin-Weller¹⁵

¹Department of Dermatology, Oregon Health and Science University, Portland, OR, USA;

²Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA; ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada; ⁴Sections of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada; ⁵Skin Health & Wellness Centre, Calgary, AB, Canada; ⁶Dermatology Research Institute, Calgary, AB, Canada; ⁷Probit Medical Research, Calgary, AB, Canada; ⁸Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany; ⁹North Campus, Kyoto Prefectural University of Medicine, Kyoto, Japan; ¹⁰Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, CO, USA; ¹¹Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; ¹²Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA;

¹³Frontier Dermatology, Mill Creek, WA; USA; ¹⁴AbbVie Inc., North Chicago, IL, USA;

¹⁵Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, Netherlands

Corresponding Author:

Eric Simpson, MD, MCR

Department of Dermatology

Oregon Health and Science University

Portland, OR

USA

simpsons@ohsu.edu

+1 (503) 418-3376

Table of Contents


Fig. S1 Proportion of patients achieving daily MCID ^a in WP-NRS in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials and (B) the Heads Up clinical trial through day 28.	4
Fig. S2 Proportion of patients achieving weekly MCID ^a in WP-NRS in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24.	6
Fig. S3 Percent improvement in daily WP-NRS estimated via LS mean in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials and (B) the Heads Up clinical trial through day 28.	8

Fig. S4 Percent improvement in weekly WP-NRS estimated via LS mean in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .05$, ***Nominal $p < .001$. ^aStatistical comparison was multiplicity adjusted, DUPI dupilumab, LS least squares, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale10

Fig. S5 Proportion of patients achieving weekly EASI ≤ 3 in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .05$, ***Nominal $p < .001$. DUPI dupilumab, EASI Eczema Area and Severity Index, UPA upadacitinib12

Fig. S6 Proportion of patients simultaneously achieving EASI ≤ 3 and WP-NRS 0/1 in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24.....14

Fig. S1 Proportion of patients achieving daily MCID^a in WP-NRS in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials and (B) the Heads Up clinical trial through day 28. For the daily WP-NRS, day 1 is the day of randomization. ***Nominal $p < .001$. ^aMCID was defined as a reduction in baseline WP-NRS score ≥ 4 among patients with a WP-NRS score ≥ 4 at baseline, ^bStatistical comparison was multiplicity adjusted, DUP1 dupilumab, MCID minimal clinically important difference, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale







Fig. S2 Proportion of patients achieving weekly MCID^a in WP-NRS in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .05$, * $p < .001$. ^aMCID was defined as a reduction in baseline WP-NRS score ≥ 4 among patients with a WP-NRS score ≥ 4 at baseline, ^bStatistical comparison was multiplicity adjusted. DUPI dupilumab, MCID minimal clinically important difference, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale**







Fig. S3 Percent improvement in daily WP-NRS estimated via LS mean in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials and (B) the Heads Up clinical trial through day 28. For the daily WP-NRS, day 1 is the day of randomization. *Nominal $p < .001$. DUPI dupilumab, LS least squares, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale**







Fig. S4 Percent improvement in weekly WP-NRS estimated via LS mean in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .05$, *Nominal $p < .001$. ^aStatistical comparison was multiplicity adjusted, DUPI dupilumab, LS least squares, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale**







Fig. S5 Proportion of patients achieving weekly EASI ≤ 3 in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .05$, *Nominal $p < .001$. DUPI dupilumab, EASI Eczema Area and Severity Index, UPA upadacitinib**






Fig. S6 Proportion of patients simultaneously achieving EASI ≤ 3 and WP-NRS 0/1 in (A) the integrated Measure Up 1 and Measure Up 2 clinical trials through week 16 and (B) the Heads Up clinical trial through week 24. *Nominal $p < .001$. DUPI dupilumab, EASI Eczema Area and Severity Index, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale**

